News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Menlo Park's Intersect ENT Latest Health/Bio IPO To Lower Target


7/15/2014 7:17:24 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Nasal implant maker Intersect ENT is the latest in the health and biotech sector to lower its IPO targets, setting price targets to raise up to $74.8 million on Monday. It originally had expected to raise $80 million.

The Menlo Park company led by CEO Lisa Earnhardt now said it plans to sell 5 million shares in a price range of between $11 and $13, which would raise $60 million. The rest would come if it sells an over-allotment that has been set aside for underwiters of the offering.

Help employers find you! Check out all the jobs and post your resume.

Read at News Release


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES